CN107278203B - 作为JANUS激酶抑制剂的4,6-取代的吡唑并[1,5-a]吡嗪 - Google Patents

作为JANUS激酶抑制剂的4,6-取代的吡唑并[1,5-a]吡嗪 Download PDF

Info

Publication number
CN107278203B
CN107278203B CN201580066136.5A CN201580066136A CN107278203B CN 107278203 B CN107278203 B CN 107278203B CN 201580066136 A CN201580066136 A CN 201580066136A CN 107278203 B CN107278203 B CN 107278203B
Authority
CN
China
Prior art keywords
pyrazol
pyrazolo
pyrazin
pent
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201580066136.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN107278203A (zh
Inventor
S.艾伦
M.L.博伊斯
M.J.基卡雷利
J.B.费尔
J.P.费希尔
J.高迪诺
E.J.希肯
R.J.欣克林
C.F.克拉泽
E.莱尔德
J.E.鲁滨逊
T.P.唐
L.E.伯吉斯
R.A.里格尔
J.费内杰
Y.萨托
K.莱夫特里斯
R.K.拉赫贾
B.L.班尼特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Array Biopharma Inc
Original Assignee
Celgene Corp
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp, Array Biopharma Inc filed Critical Celgene Corp
Publication of CN107278203A publication Critical patent/CN107278203A/zh
Application granted granted Critical
Publication of CN107278203B publication Critical patent/CN107278203B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
CN201580066136.5A 2014-12-05 2015-12-04 作为JANUS激酶抑制剂的4,6-取代的吡唑并[1,5-a]吡嗪 Expired - Fee Related CN107278203B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462088068P 2014-12-05 2014-12-05
US62/088,068 2014-12-05
PCT/US2015/064062 WO2016090285A1 (en) 2014-12-05 2015-12-04 4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS

Publications (2)

Publication Number Publication Date
CN107278203A CN107278203A (zh) 2017-10-20
CN107278203B true CN107278203B (zh) 2020-05-19

Family

ID=55069089

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580066136.5A Expired - Fee Related CN107278203B (zh) 2014-12-05 2015-12-04 作为JANUS激酶抑制剂的4,6-取代的吡唑并[1,5-a]吡嗪

Country Status (29)

Country Link
US (3) US10189845B2 (enExample)
EP (2) EP3878451A1 (enExample)
JP (2) JP6641373B2 (enExample)
KR (1) KR20170090476A (enExample)
CN (1) CN107278203B (enExample)
AU (1) AU2015357585B2 (enExample)
BR (1) BR112017011798A2 (enExample)
CA (1) CA2969709A1 (enExample)
CL (1) CL2017001422A1 (enExample)
CO (1) CO2017006674A2 (enExample)
CR (1) CR20170309A (enExample)
DK (1) DK3227297T3 (enExample)
ES (1) ES2865483T3 (enExample)
HR (1) HRP20210501T1 (enExample)
HU (1) HUE054371T2 (enExample)
IL (1) IL252656A0 (enExample)
MX (1) MX386316B (enExample)
MY (1) MY191016A (enExample)
PH (1) PH12017501032A1 (enExample)
PL (1) PL3227297T3 (enExample)
PT (1) PT3227297T (enExample)
RS (1) RS61693B1 (enExample)
RU (2) RU2021102805A (enExample)
SG (1) SG11201704542SA (enExample)
SI (1) SI3227297T1 (enExample)
TW (1) TWI725004B (enExample)
UA (1) UA120065C2 (enExample)
WO (1) WO2016090285A1 (enExample)
ZA (1) ZA201704494B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017156493A1 (en) 2016-03-11 2017-09-14 Denali Therapeutics Inc. Compounds, compositions, and methods
PL3227297T3 (pl) 2014-12-05 2021-10-25 Array Biopharma, Inc. 4,6 podstawione-pyrazolo[1,5-a]pirazyny jako inhibitory kinaz janusowych
RU2718902C2 (ru) * 2016-02-24 2020-04-15 Пфайзер Инк. Производные пиразоло[1,5-а]пиразин-4-ила в качестве jak-ингибиторов
PE20190395A1 (es) 2016-06-16 2019-03-13 Denali Therapeutics Inc Pirimidin-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para el uso en el tratamiento de trastornos neurodegenerativos
GB201617758D0 (en) * 2016-10-20 2016-12-07 Almac Discovery Limited Pharmaceutical compounds
CA3049136C (en) 2017-01-18 2022-06-14 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyrazine compounds as ret kinase inhibitors
WO2018217946A1 (en) * 2017-05-24 2018-11-29 Denali Therapeutics Inc. Compounds, compositions and methods
EP3668858A1 (en) 2017-08-14 2020-06-24 Pfizer Inc Pyrazolo[1,5-a]pyrazin-4-yl and related derivatives
CA3087354C (en) 2018-01-18 2023-01-03 Array Biopharma Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
WO2019143994A1 (en) 2018-01-18 2019-07-25 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
CA3087578C (en) 2018-01-18 2023-08-08 Array Biopharma Inc. Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors
CN112996794A (zh) 2018-09-10 2021-06-18 阿雷生物药品公司 作为ret激酶抑制剂的稠合杂环化合物
JP7256291B2 (ja) * 2019-04-12 2023-04-11 プライムジーン（ベイジン）カンパニー リミテッド ピラゾロピラジン誘導の化合物、医薬組成物およびその使用
KR102503349B1 (ko) 2019-05-14 2023-02-23 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
CN113150012B (zh) * 2020-01-22 2023-03-24 浙江海正药业股份有限公司 吡唑并[1,5-a]吡嗪类衍生物及其制备方法和用途
WO2021198980A1 (en) 2020-04-04 2021-10-07 Pfizer Inc. Methods of treating coronavirus disease 2019
US12006366B2 (en) 2020-06-11 2024-06-11 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
IL312782A (en) * 2021-11-12 2024-07-01 Soter Biopharma Pte Ltd Pyrazolo fused ring compound and use thereof
WO2024235167A1 (zh) * 2023-05-12 2024-11-21 海南康哲美丽科技有限公司 一种吡唑并吡嗪类化合物及其晶型的制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102762570A (zh) * 2010-02-18 2012-10-31 阿尔米雷尔有限公司 作为jak抑制剂的吡唑衍生物
CN102985424A (zh) * 2010-04-14 2013-03-20 阵列生物制药公司 5,7-取代的-咪唑并[1,2-c]嘧啶
CN103987713A (zh) * 2011-10-12 2014-08-13 阵列生物制药公司 5,7-取代的咪唑并[1,2-c]嘧啶

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010089171A (ko) 1998-08-21 2001-09-29 추후제출 퀴나졸린 유도체
DE102007032349A1 (de) * 2007-07-11 2009-01-15 Bayer Healthcare Ag Imidazo-, Pyrazolopyrazine und Imidazotriazine und ihre Verwendung
KR101790255B1 (ko) * 2009-12-23 2017-10-26 다케다 야쿠힌 고교 가부시키가이샤 Ｓｙｋ 억제제로서의 융합된 헤테로방향족 피롤리디논
EP2526102B1 (en) * 2010-01-22 2017-03-08 Fundación Centro Nacional de Investigaciones Oncológicas Carlos III Inhibitors of PI3 kinase
US20110241987A1 (en) * 2010-04-01 2011-10-06 Smart Technologies Ulc Interactive input system and information input method therefor
WO2013143663A1 (en) * 2012-03-28 2013-10-03 Merck Patent Gmbh Bicyclic pyrazinone derivatives
PL3227297T3 (pl) 2014-12-05 2021-10-25 Array Biopharma, Inc. 4,6 podstawione-pyrazolo[1,5-a]pirazyny jako inhibitory kinaz janusowych

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102762570A (zh) * 2010-02-18 2012-10-31 阿尔米雷尔有限公司 作为jak抑制剂的吡唑衍生物
CN102985424A (zh) * 2010-04-14 2013-03-20 阵列生物制药公司 5,7-取代的-咪唑并[1,2-c]嘧啶
CN103987713A (zh) * 2011-10-12 2014-08-13 阵列生物制药公司 5,7-取代的咪唑并[1,2-c]嘧啶

Also Published As

Publication number Publication date
US10730880B2 (en) 2020-08-04
HRP20210501T1 (hr) 2021-05-14
MX386316B (es) 2025-03-18
US10189845B2 (en) 2019-01-29
CR20170309A (es) 2018-02-02
SG11201704542SA (en) 2017-07-28
WO2016090285A1 (en) 2016-06-09
PH12017501032A1 (en) 2017-11-27
HUE054371T2 (hu) 2021-09-28
ES2865483T3 (es) 2021-10-15
PL3227297T3 (pl) 2021-10-25
US20170362240A1 (en) 2017-12-21
IL252656A0 (en) 2017-07-31
RU2017123387A3 (enExample) 2019-06-03
US20190177328A1 (en) 2019-06-13
RU2742938C2 (ru) 2021-02-11
EP3878451A1 (en) 2021-09-15
TWI725004B (zh) 2021-04-21
RS61693B1 (sr) 2021-05-31
AU2015357585B2 (en) 2020-07-02
CL2017001422A1 (es) 2018-01-05
CO2017006674A2 (es) 2017-10-20
EP3227297A1 (en) 2017-10-11
JP2020055859A (ja) 2020-04-09
KR20170090476A (ko) 2017-08-07
US20200291039A1 (en) 2020-09-17
AU2015357585A1 (en) 2017-07-13
CA2969709A1 (en) 2016-06-09
EP3227297B1 (en) 2021-01-20
SI3227297T1 (sl) 2021-04-30
RU2021102805A (ru) 2021-02-12
UA120065C2 (uk) 2019-09-25
US11028093B2 (en) 2021-06-08
BR112017011798A2 (pt) 2017-12-26
CN107278203A (zh) 2017-10-20
TW201632523A (zh) 2016-09-16
DK3227297T3 (da) 2021-04-06
ZA201704494B (en) 2022-03-30
RU2017123387A (ru) 2019-01-11
JP2018507167A (ja) 2018-03-15
JP6641373B2 (ja) 2020-02-05
PT3227297T (pt) 2021-04-09
MX2017007284A (es) 2017-08-25
MY191016A (en) 2022-05-28

Similar Documents

Publication Publication Date Title
CN107278203B (zh) 作为JANUS激酶抑制剂的4,6-取代的吡唑并[1,5-a]吡嗪
JP6530792B2 (ja) Ｓｙｋ阻害剤
TWI648277B (zh) 作為ｐｉ３ｋ抑制劑之雜環基胺
JP2017518276A (ja) ブルトン型チロシンキナーゼ（ｂｔｋ）インヒビターとしての多フルオロ置換化合物
TW201605866A (zh) 可用作ｐｉｍ激酶抑制劑之呋喃并－及噻吩并－吡啶甲醯胺化合物
CN112437774A (zh) 化合物
TW201734020A (zh) 布魯頓氏酪胺酸激酶抑制劑及其使用方法
KR20230123471A (ko) 화합물, 조성물 및 방법
TW202110848A (zh) 取代的稠合雙環類衍生物、其製備方法及其在醫藥上的應用
CN114981270B (zh) Mll1抑制剂和抗癌剂
CN113227091A (zh) 作为am2受体抑制剂的杂环螺-化合物
CN120981466A (zh) 作为egfr抑制剂的大环氨基吡啶化合物
CN116507608A (zh) 化合物、组合物和方法
CN116390727A (zh) 作为lrrk2抑制剂的n-连接异喹啉酰胺及其药物组合物和用途
HK1238236B (en) 4,6-substituted-pyrazolo[1,5-a]pyrazines as janus kinase inhibitors
HK40064826A (en) Substituted fused bicyclic derivative, preparation method therefor, and application thereof in medicines
HK40042708A (en) Compounds
HK1228913A1 (en) Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20200519